Core Viewpoint - Avis Budget Group, Inc. is facing a class action lawsuit due to alleged misleading statements and undisclosed information regarding its fleet rotation strategy, which has led to significant financial losses and impairment charges [2][3]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Avis securities between February 16, 2024, and February 10, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Avis Budget - The lawsuit claims that Avis Budget executed a plan to aggressively accelerate fleet rotation, which shortened the useful life of vehicles in the Americas segment, reducing their recoverable value [2]. - As a result of this strategy, Avis Budget is expected to recognize billions of dollars in impairment charges and face substantial losses [2]. - The financial performance of Avis Budget was significantly negatively impacted, leading to an overstated financial condition and business outlook [2]. Group 3: Financial Results and Leadership Changes - On February 11, 2025, Avis Budget reported a quarterly loss of $1.96 billion, or $55.66 per share, compared to a profit of $259 million, or $7.10 per share, for the same period the previous year [3]. - The loss was attributed to a change in strategy regarding fleet rotations, resulting in a one-time non-cash impairment of $2.3 billion and additional non-cash charges of $180 million [3]. - Following the announcement of these results, Avis Budget's stock price dropped nearly 7% [3]. - The CEO, Joseph A. Ferraro, is set to step down, transitioning to a Board Advisor role, with Brian Choi taking over as CEO on July 1, 2025 [3].

Core Insights - The ATALANTA-1 Phase 1/2 study of GLPG5101 shows promising efficacy and safety in treating relapsed/refractory indolent non-Hodgkin lymphoma, with a 97% complete response rate and 100% minimal residual disease negativity in evaluable patients [1][3][4] - The study highlights the advantages of a decentralized manufacturing platform, allowing for fresh CAR-T cell administration within seven days, which mitigates disease progression risks and spares patients from additional chemotherapy [2][5] Efficacy and Safety - In Cohort 3, 34 patients were enrolled, with 32 receiving GLPG5101; 94% received fresh CAR-T cells, and 93% were treated within seven days of manufacturing [1][3] - The complete response rate was 97%, with 31 out of 32 patients responding to treatment, and 100% of evaluable patients being MRD negative [3][4] - The 12-month progression-free survival rate was reported at 97%, with no relapses noted [3][4] Manufacturing and Administration - The decentralized manufacturing platform enables a median vein-to-vein time of seven days, allowing for timely treatment without the need for cytotoxic bridging therapy [2][5] - The final product showed a significant increase in early phenotype CD4+ and CD8+ CAR-T cells compared to the starting material [3] Study Design and Objectives - The ATALANTA-1 study is evaluating GLPG5101 in multiple hematological malignancies, focusing on safety, efficacy, and the feasibility of decentralized manufacturing [4] - The primary objective of the Phase 1 part is to assess safety and determine the recommended dose for Phase 2, while the Phase 2 part aims to evaluate the Objective Response Rate [4]

Core Viewpoint - Avis Budget Group, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 16, 2024, and February 10, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024, which shortened the useful life of most vehicles in the Americas segment [2] - This acceleration is alleged to have led to billions of dollars in impairment charges and substantial losses for the company [2] - The financial and business prospects of Avis Budget were reportedly overstated, resulting in materially false and misleading public statements by the defendants [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 24, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities cases [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Avis Budget Group, Inc. regarding a class action lawsuit due to allegations of materially false and misleading statements made by the company during a specified class period [1][2]. Allegations - The complaint alleges that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024, which shortened the useful life of most vehicles in the Americas segment, reducing their recoverable value [1]. - As a result of this acceleration, Avis Budget is expected to recognize billions of dollars in impairment charges and incur substantial losses, negatively impacting the company's financial results [1]. - The allegations suggest that the company's financial and business prospects were overstated, making public statements materially false and misleading throughout the relevant period [1]. Class Action Details - The class period for the lawsuit is from February 16, 2024, to February 10, 2025, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is June 24, 2025, and there is no cost or obligation to participate in the case [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 24, 2025 [1]. Group 1: Class Action Details - Investors who purchased Avis Budget securities between February 16, 2024, and February 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by June 24, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which negatively impacted the value of its vehicles and led to billions in impairment charges [5]. - The claims suggest that Avis Budget's financial results and business prospects were overstated, resulting in investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from February 16, 2024, to February 10, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by June 24, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which significantly shortened the useful life of its vehicles and led to billions in impairment charges [4]. - The allegations suggest that these misstatements had a significant negative impact on Avis Budget's financial results and overstated its business prospects [4].

Core Insights - Johnson & Johnson announced promising results from a Phase 1b study of JNJ-90014496, a dual-targeting CAR T-cell therapy for relapsed or refractory large B-cell lymphoma, showing a 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose [1][2] Company Overview - Johnson & Johnson is committed to advancing innovative therapies for patients with B-cell malignancies, emphasizing their long-term dedication to addressing unmet medical needs [2][4] - The company is expanding its pipeline of CAR T therapies through a collaboration with AbelZeta Inc. to develop next-generation CAR T-cell therapies [2][3] Industry Context - Large B-cell lymphoma, particularly diffuse large B-cell lymphoma, accounts for approximately 40% of all non-Hodgkin lymphoma cases globally, with an estimated 150,000 new cases diagnosed each year [3] - Current single-antigen-targeting CD19 CAR T therapies provide long-term remissions for only about 40% of patients, highlighting the need for innovative treatment options [2][3]

Core Viewpoint - A class action securities lawsuit has been filed against Avis Budget Group, Inc. alleging securities fraud that negatively impacted investors between February 16, 2024, and February 10, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024 [2]. - This acceleration allegedly shortened the useful life of most vehicles in the Americas segment, reducing their recoverable value [2]. - As a result, Avis Budget is expected to recognize billions of dollars in impairment charges and incur substantial losses [2]. - The financial and business prospects of Avis Budget were overstated, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until June 24, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Avis Budget Group, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from February 16, 2024, to February 10, 2025 [1] Group 1: Allegations Against Avis Budget Group - The complaint alleges that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024, which shortened the useful life of most vehicles in the Americas segment [1] - This acceleration is claimed to have reduced the recoverable value of the vehicles, leading to billions of dollars in impairment charges and substantial losses for the company [1] - As a result, the financial and business prospects of Avis Budget were overstated, and the public statements made by the defendants were materially false and misleading [1] Group 2: Class Action Details - Shareholders who purchased shares of CAR during the specified class period are encouraged to register for the class action, with a deadline of June 24, 2025, to seek lead plaintiff status [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] - Participation in the case incurs no cost or obligation for the shareholders [2] Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - Avis Budget Group, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 16, 2024, and February 10, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024, which shortened the useful life of most vehicles in the Americas segment [2]. - This acceleration is alleged to have reduced the recoverable value of the vehicles, leading to billions of dollars in impairment charges and substantial losses for the company [2]. - As a result, the financial and business prospects of Avis Budget were overstated, and the public statements made by the defendants were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 24, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4].